Results 11 to 20 of about 1,009,444 (403)

Increased memory B cell potency and breadth after a SARS-CoV-2 mRNA boost

Nature, 2022
The Omicron variant of SARS-CoV-2 infected many vaccinated and convalescent individuals1–3. Despite the reduced protection from infection, individuals who received three doses of an mRNA vaccine were highly protected from more serious consequences of ...
Frauke Muecksch, Zijun Wang, A. Cho, C. Gaebler, Tarek Ben Tanfous, Justin DaSilva, Eva Bednarski, Victor Ramos, Shuaizhou Zong, B. Johnson, Raphael Raspe, Dennis J. Schaefer-Babajew, I. Shimeliovich, M. Daga, Kai-Hui Yao, F. Schmidt, Katrina G. Millard, Martina Turroja, M. Jankovic, Thiago Y. Oliveira, A. Gazumyan, M. Caskey, T. Hatziioannou, P. Bieniasz, M. Nussenzweig   +24 more
semanticscholar   +1 more source

Interpretation of machine learning models using shapley values: application to compound potency and multi-target activity predictions

Journal of Computer-Aided Molecular Design, 2020
Difficulties in interpreting machine learning (ML) models and their predictions limit the practical applicability of and confidence in ML in pharmaceutical research.
Raquel Rodríguez-Pérez, J. Bajorath
semanticscholar   +1 more source

Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo

Journal of Experimental Medicine, 2020
Human monoclonal antibody potency in vitro does not uniformly correlate with its in vivo neutralization of SARS-CoV-2. Antibody Fc-effector function is important for in vivo neutralization, and antibody combinations show superior efficacy compared with ...
A. Schäfer, Frauke Muecksch, Julio C. C. Lorenzi, S. Leist, M. Cipolla, S. Bournazos, F. Schmidt, R. M. Maison, A. Gazumyan, David R. Martinez, R. Baric, D. Robbiani, T. Hatziioannou, J. Ravetch, P. Bieniasz, R. Bowen, M. Nussenzweig, T. Sheahan   +17 more
semanticscholar   +1 more source

Mapping cannabis potency in medical and recreational programs in the United States

PLoS ONE, 2020
Cannabis related online searches are associated with positive attitudes toward medical cannabis, particularly when information is obtained from dispensaries.
M. Cash, K. Cunnane, Chuyin Fan, E. Romero-Sandoval   +3 more
semanticscholar   +1 more source

Association of High-Potency Cannabis Use With Mental Health and Substance Use in Adolescence

JAMA psychiatry, 2020
Key Points Question Does use of high-potency cannabis (compared with use of low-potency cannabis) increase risks for problems resulting from cannabis use, common mental disorders, and psychotic experiences after controlling for early-life mental health ...
L. Hines, T. Freeman, S. Gage, S. Zammit, M. Hickman, M. Cannon, M. Munafo, J. Macleod, J. Heron   +8 more
semanticscholar   +1 more source

Durkheim’s totemic principle, shamanism and Southern African San religions

HTS Teologiese Studies/Theological Studies, 2021
The study reappraised Emile Durkheim’s totemic principle in relation to the origins of religion and culture, using, amongst others, speech act theory and recent southern African epistemologies, especially David Lewis-Williams’ theory of shamanism ...
Richard A. Northover
doaj   +1 more source

Yield Performance of Locally Selected Cocoa Clones in North Luwu [PDF]

, 2015
Participatory selection in North Luwu District selected some locally cocoa clones, of which MCC 01 and MCC 02 the most promising to be developed as clonal material.
Imran, I. (Imran), Sari, I. A. (Indah), Soesilo, A. W. (Agung)   +2 more
core   +3 more sources

Distribution and the potential growth of ganitri ( Elaeocarpus ganitrus Roxb ) in Central Java

Jurnal Ilmu Kehutanan, 2014
Ganitri (Elaeocarpus ganitrus Roxb) is a multi-purpose species that has the potential to be developed. This species has been known and cultivated by people, particularly in the region of Central Java.
Asep Rohandi, Gunawan Gunawan
doaj   +1 more source

Anti-cancer effects and mechanism of actions of aspirin analogues in the treatment of glioma cancer [PDF]

, 2012
INTRODUCTION: In the past 25 years only modest advancements in glioma treatment have been made, with patient prognosis and median survival time following diagnosis only increasing from 3 to 7 months.
A. A. Hill, A. Altinkaya, A. Baborie, A. Bahl, A. Brodbelt, A. Brodbelt, A. Brodbelt, A. Brodbelt, A. Chalmers, A. Dubocq, A. Eason, A. Elmahdi, A. Frary, A. Frary, A. Gerhard, A. Gullan, A. Hajitou, A. J. Frary, A. Jackson, A. James, A. James, A. Joannides, A. Kia, A. Niranjan, A. O'Brien, A. Shaw, A. Shenoy, A. Shivane, A. Shoakazemi, A. Singh, A. Singleton, A. Sofat, A. Sottoriva, A. Williamson, A. Young, A. Young, B. Hacking, B. Harding, B. Haylock, B. Haylock, B. Haylock, B. Herron, C. Chatelain, C. Crosby, C. Davis, C. Hanemann, C. L. Nigro, C. Lawrence, C. O. Hanemann, C. Romanowski, C. Schmidberger, C. Walker, C. Walker, C. Walker, C. Watts, C. Watts, C. Watts, D. A. Jellinek, D. Bowyer, D. Cavers, D. Conkey, D. Coope, D. Crooks, D. Crooks, D. Crooks, D. du Plessis, D. Elder, D. G. O'Donovan, D. Husband, D. J. Coope, D. Kondziolka, D. Parkinson, D. Sheer, D. Thompson, D. W. Ellison, E. A. Chiocca, E. Clarke, E. Ercolano, E. Goessl, E. Hatzimichael, E. Healy, E. McGrath, E. Murray, F. Harris, F. McKevitt, F. Roncaroli, F. Roncaroli, F. Rowther, F. Rowther, F. Rowther, F. Turkheimer, G. Cruickshank, G. Hall, G. Hall, G. J. Pilkington, G. J. Pilkington, G. Pilkington, G. Pilkington, G. Pilkington, G. Pilkington, G. Thompson, G. Wall, G. Zilidis, H. Coley, H. Dogra, H. Kano, H. Kardooni, H. Wong, I. C. Morley, I. Corbett, I. Craven, I. Nicholl, I. Noorani, I. Qaddoumi, I. R. Whittle, I. Spiteri, J. Alder, J. Baily, J. Bambrough, J. Bambrough, J. Bomalaski, J. Darling, J. Darling, J. Darling, J. Darling, J. Darling, J. Dunn, J. Dunn, J. Harney, J. Holliday, J. Ironside, J. Larsen, J. Leggate, J. Logan, J. M. Przystal, J. N. Jeyapalan, J. Simpson, J. Singh, J. Tavare, K. Ashkan, K. Ashkan, K. Ashton, K. Ashton, K. Ashton, K. Chen, K. Das, K. E. Hatherell, K. Herholz, K. Hopkins, K. Hopkins, K. Janczar, K. Karabatsou, K. Karabatsou, K. Karakoula, K. Karakoula, K. Kroese, K. M. Kurian, K. M. Kurian, K. M. Kurian, K. M. Prise, K. McCarthy, K. O'Neil, K. Phipps, K. Prise, L. Brazil, L. Donovan, L. Evans, L. Lattanzio, L. Lunsford, L. Mohsen, L. Rada, L. Shaw, L. Spinelli, L. Steele, L. Taggart, L. Wallace, L. Zhou, M. A. Mumin, M. Altinkaya, M. Anand, M. Anand, M. Arora, M. Barczyk, M. Boissinot, M. Bradley, M. C. Schmid, M. Diaz, M. Donnelly, M. Frame, M. Jenkinson, M. Jenkinson, M. Jenkinson, M. Keeling, M. Mackinnon, M. McLean, M. Morris, M. R. Morris, M. Williams, N. A. Pullen, N. A. Pullen, N. Burnet, N. Cohen, N. D. Mazarakis, N. Hoggard, N. Marko, N. Nianiaris, N. Potter, N. R. Leslie, N. Rathi, N. Rathi, N. Syed, O. Sansom, O. Thomas, P. Brennan, P. Collins, P. Grundy, P. J. Mintz, P. Metherall, P. Singh, P. Singh, P. Szlosarek, P. Tibarewal, P. Welsby, Q. An, R. Beaney, R. Bhangoo, R. Blake, R. Brock, R. G. Tatevossian, R. Grundy, R. Hamilton, R. Hayward, R. Hinz, R. Jackson, R. Jena, R. Lea, R. McConnell, R. Muirhead, R. P. Pangeni, R. Rahman, S. Al-Rashid, S. Ammoun, S. Ammoun, S. Bell, S. Bell, S. Birks, S. Birks, S. Birks, S. Birks, S. Green, S. Hafizi, S. Hafizi, S. Higgins, S. J. Price, S. J. Price, S. J. Price, S. Jefferies, S. Kokkinos, S. Lawler, S. Leow-Dyke, S. Leow-Dyke, S. Leow-Dyke, S. Mashal, S. McQuaid, S. Price, S. Price, S. Price, S. Price, S. Saini, S. Scott, S. Shepherd, S. Smith, S. T. Al Rashid, S. Tavare, S. Wilkins, S. Williams, S. Williams, T. Crook, T. Dawson, T. Dawson, T. Dawson, T. Flannery, T. Flannery, T. Gaissmaier, T. J. Warr, T. Jacques, T. Jaunky, T. Lawson, T. Smith, T. Van Meter, T. Warr, T. Warr, T. Warr, T. Warr, T. Warr, V. Beckett, V. Berry, V. Bosak, V. Brunton, V. Hurwitz, V. Iyer, V. Iyer, V. Lupson, V. Petinou, W. Harkness, W. Stewart, W. Stewart, Y. Majani, Y. Zhang, Z. Hanzely, Z. Hanzely, Z. Maherally, Z. Su   +312 more
core   +1 more source

Methods Matter: Standard Production Platforms for Recombinant AAV Produce Chemically and Functionally Distinct Vectors

Molecular Therapy: Methods & Clinical Development, 2020
Different approaches are used in the production of recombinant adeno-associated virus (rAAV). The two leading approaches are transiently transfected human HEK293 cells and live baculovirus infection of Spodoptera frugiperda (Sf9) insect cells ...
Neil G. Rumachik, Stacy A. Malaker, Nicole Poweleit, Lucy H. Maynard, Christopher M. Adams, Ryan D. Leib, Giana Cirolia, Dennis Thomas, Susan Stamnes, Kathleen Holt, Patrick Sinn, Andrew P. May, Nicole K. Paulk   +12 more
doaj   +1 more source